+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Oral Insulin"

From
Diabetes Drugs - Global Strategic Business Report - Product Thumbnail Image

Diabetes Drugs - Global Strategic Business Report

  • Report
  • March 2025
  • 196 Pages
  • Global
From
Non-Injectable Insulin Market Report 2025 - Product Thumbnail Image

Non-Injectable Insulin Market Report 2025

  • Report
  • March 2025
  • 200 Pages
  • Global
From
From
Anti-Diabetic Drug Market - Forecasts from 2025 to 2030 - Product Thumbnail Image

Anti-Diabetic Drug Market - Forecasts from 2025 to 2030

  • Report
  • January 2025
  • 140 Pages
  • Global
From
From
From
Global Markets for Diabetes Therapeutics and Diagnostics - Product Thumbnail Image

Global Markets for Diabetes Therapeutics and Diagnostics

  • Report
  • August 2023
  • 336 Pages
  • Global
From
From
From
From
From
From
From
From
  • 20 Results (Page 1 of 1)
Loading Indicator

The Oral Insulin market is a subset of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs that are taken orally to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Oral Insulin is a relatively new form of treatment, and is seen as a more convenient and less invasive alternative to traditional insulin injections. It is also seen as a potential solution to the problem of poor adherence to insulin therapy. Oral Insulin is still in the early stages of development, and there are currently no approved oral insulin products on the market. However, several companies are researching and developing oral insulin products, and some have already completed clinical trials. Companies in the Oral Insulin market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and Pfizer. Show Less Read more